細(xì)胞名稱

TFK-1人膽管癌細(xì)胞

貨物編碼

BFN60808817

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級(jí)

1

用途限制

僅供科研   2類

培養(yǎng)體系

90%DMEM+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡(jiǎn)介

TFK-1人膽管癌細(xì)胞取自63歲男性供體。該細(xì)胞源于DSMZ

注釋

Doubling time: ~37 hours, at 40th passage (PubMed=8693487); ~40 hours (DSMZ).

Omics: Deep exome analysis.

Misspelling: TFKK-1; PubMed=22490663 supplementary figure 2.

基因突變

/

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        10

D5S818        9,12

D7S820        10 (DSMZ)

10,11 (RCB; TKG)

D13S317        14

D16S539        9

TH01        6

TPOX        8

vWA        14,17

參考文獻(xiàn)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122

Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A.

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.

Biochem. Biophys. Res. Commun. 421:98-104(2012)

CLPUB00275

Zach S., Birgin E., Ruckert F.

Primary cholangiocellular carcinoma cell lines.

J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442

Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H., Bardeesy N.

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.

Cancer Discov. 6:727-739(2016)

PubMed=31077409; DOI=10.1002/hep.30704

Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Hepatology 70:1614-1630(2019)